Bruce Carleton, PharmD, FCP, FISPE
Professor and Division Chief, Translational Therapeutics
Principal investigator of the Canadian Pharmacogenomics Network for Drug Safety. CPNDS is helping to solve drug safety problems by developing genetic tests that predict which patients are at risk of serious ADRs. The work of CPNDS is to find drug safety solutions, not just find the genetic basis of ADRs.
Colin Ross, PhD
Co-principal investigator of the Genome Canada GO-PGx Study to explore the genetic basis of serious adverse drug reactions in children. We are researching pharmacogenetic tests to predict which patients are at risk of serious ADRs.